These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12037157)

  • 21. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Tattevin P; Bareau B; Camus C
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675091
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    Mycoses; 2012 May; 55(3):244-56. PubMed ID: 21790799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient.
    Consigny S; Dhedin N; Datry A; Choquet S; Leblond V; Chosidow O
    Clin Infect Dis; 2003 Jul; 37(2):311-3. PubMed ID: 12856225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia.
    Torres A; Serrano J; Rojas R; Martín V; Martín C; Tabares S; Molina JR; Capote M; Martínez F; Gómez P; Sánchez-García J
    Eur J Haematol; 2010 Mar; 84(3):271-3. PubMed ID: 19878274
    [No Abstract]   [Full Text] [Related]  

  • 25. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole.
    Antachopoulos C; Papakonstantinou E; Dotis J; Bibashi E; Tamiolaki M; Koliouskas D; Roilides E
    J Pediatr Hematol Oncol; 2005 May; 27(5):283-5. PubMed ID: 15891566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Marty FM; Lowry CM
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675093
    [No Abstract]   [Full Text] [Related]  

  • 27. Voriconazole versus amphotericin B for invasive aspergillosis.
    Blot F; Edé C; Nitenberg GM
    N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12490695
    [No Abstract]   [Full Text] [Related]  

  • 28. [New development in the treatment of deep-seated mycoses].
    Maesaki S
    Nihon Naika Gakkai Zasshi; 2007 Sep; 96(9):1993-8. PubMed ID: 17929445
    [No Abstract]   [Full Text] [Related]  

  • 29. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D; Buadi FK; McClune B
    Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of antifungal therapy in a neutropenic murine model of Neoscytalidium dimidiatum infection.
    Ruíz-Cendoya M; Madrid H; Pastor J; Guarro J
    Int J Antimicrob Agents; 2010 Feb; 35(2):152-5. PubMed ID: 20005680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on the use of antifungal agents.
    Martinez R
    J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful use of combination antifungal therapy in the treatment of coccidioides meningitis.
    Antony SJ; Jurczyk P; Brumble L
    J Natl Med Assoc; 2006 Jun; 98(6):940-2. PubMed ID: 16775917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.
    Manfredi R; Sabbatani S
    Scand J Infect Dis; 2006; 38(10):950-1. PubMed ID: 17008248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of newer antifungal therapies in clinical practice: what do the data tell us?
    Perfect JR
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):15-23. PubMed ID: 15651178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole.
    Forestier E; Remy V; Lesens O; Martinot M; Hansman Y; Eisenmann B; Christmann D
    Eur J Clin Microbiol Infect Dis; 2005 May; 24(5):347-9. PubMed ID: 15889298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
    Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
    J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
    Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
    Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.